However, a high expression ratio between Gene 33 and EGFR is positively associated with resistance to the EGFR inhibitor erlotinib by a panel of cancer cells, including human NSCLC cells, bladder cancer cells, and head and neck squamous cell carcinoma cells [157]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.